CAS 327031-55-0

6-Methyl-3-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)-5H-[1,2,4]triazino[5,6-b]indole

CAS: 327031-55-0

Formula: C₁₇H₁₅N₇

Purezza: 95%

Colore e forma: Solid

Peso molecolare: 317.3479

Ref: IN-DA01BIWH

VLX600

CAS: 327031-55-0

VLX600

Purezza: ≥98%

Peso molecolare: 317.35g/mol

Ref: 54-BUP06600

VLX600

CAS: 327031-55-0

VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.

Formula: C₁₇H₁₅N₇

Purezza: 98.62%

Colore e forma: Solid

Peso molecolare: 317.35

Ref: TM-T8500

VLX600

Prodotto controllato

CAS: 327031-55-0

Applications VLX600 is a compound showing cytotoxicity against cancer cells. Selective towards malignant cells and necrosis inductor in colon cancer cells.
References Zhang, X. et al.: Nat. Commun., 5, 114 (2014);

Formula: C₁₇H₁₅N₇

Colore e forma: Neat

Peso molecolare: 317.35

Ref: TR-V757175

VLX600

CAS: 327031-55-0

VLX600 is a mitochondria-targeted oxidative phosphorylation inhibitor that has been shown to inhibit the growth of cancer cells in vitro and in vivo. VLX600 has been shown to significantly kill tumour cells by inhibiting the production of ATP, which is necessary for cell division. VLX600 also prevents the formation of reactive oxygen species, which can damage DNA and proteins and lead to cell death. VLX600 has been shown to have significant cytotoxicity in various carcinoma cell lines, including human breast carcinoma, prostate carcinoma, and lung adenocarcinoma cell lines.
Vlx600 is a novel therapeutic agent for treatment of eye disorders such as age-related macular degeneration (AMD), retinal detachment, and dry eye syndrome (DES). This drug inhibits mitochondrial metabolism by binding to complex I of the electron transport chain, leading to increased levels of reactive oxygen species. This inhibition leads to decreased levels of ATP production and

Formula: C₁₇H₁₅N₇

Purezza: Min. 95%

Peso molecolare: 317.35 g/mol

Ref: 3D-CNA03155